Novel Hsp90 Inhibitor C086 Potently Inhibits Non-Small Cell Lung Cancer Cells As A Single Agent Or In Combination With Gefitinib

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Ourari-Dhahri B, Ben Slima H, Ben Amar J, et al. Management of non small cell lung cancer. Tunis Med. 2012;90(12):847–851.23247782
   PubMedGoogle Scholar
• Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61(2):91–112. doi:10.3322/caac.2010221303969
   PubMed Web of Science ®Google Scholar
• Levitzki A. EGF receptor as a therapeutic target. Lung Cancer. 2003;41:S9–S14. doi:10.1016/S0169-5002(03)00134-X
   PubMed Web of Science ®Google Scholar
• Ferrazzi A, Russo I, Pasello G, Alaibac M. Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: a case report and review of the literature. Exp Ther Med. 2016;11(1):197–200. doi:10.3892/etm.2015.288126889239
   PubMed Web of Science ®Google Scholar
• Codony-Servat C, Codony-Servat J, Karachaliou N, et al. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). Oncotarget. 2017;8(29):47305–47316. doi:10.18632/oncotarget.1762528521301
   PubMedGoogle Scholar
• Al Mamun Bhuyan A, Wagner T, Cao H, Lang F. Triggering of suicidal erythrocyte death by gefitinib. Cell Physiol Biochem. 2017;41(4):1697–1708. doi:10.1159/00047182328359067
   PubMedGoogle Scholar
• Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–181. doi:10.1038/nrc208817318210
   PubMed Web of Science ®Google Scholar
• Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2(1):57–62. doi:10.1371/journal.pmed.0020017
   Web of Science ®Google Scholar
• Wegele H, Müller L, Buchner J. Hsp70 and Hsp90-a relay team for protein folding. Rev Physiol Biochem Pharmacol. 2004;151:1–44. doi:10.1007/s10254-003-0021-114740253
   PubMed Web of Science ®Google Scholar
• Richter K, Hendershot LM, Freeman BC. The cellular world according to Hsp90. Nat Struct Mol Biol. 2007;14(2):90–94. doi:10.1038/nsmb0207-9017277798
   PubMed Web of Science ®Google Scholar
• Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci. 2007;1113(1):202–216. doi:10.1196/annals.1391.01217513464
   PubMedGoogle Scholar
• Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 2003;3(3):213–217.12676580
   PubMed Web of Science ®Google Scholar
• Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res. 2012;18(1):64–76. doi:10.1158/1078-0432.CCR-11-100022215907
   PubMed Web of Science ®Google Scholar
• Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci. 2007;32(3):517–530.17536171
   PubMed Web of Science ®Google Scholar
• Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res. 2007;13(6):1625–1629. doi:10.1158/1078-0432.CCR-06-227017363512
   PubMed Web of Science ®Google Scholar
• Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10(8):537–549. doi:10.1038/nrc288720651736
   PubMed Web of Science ®Google Scholar
• Gallegos Ruiz MI, Floor K, Roepman P, et al. Integration of gene dosage and gene expression in NSCLC, identification of Hsp90 as potential target. PLoS One. 2008;3(3):e0001722. doi:10.1371/journal.pone.000172218320023
   PubMed Web of Science ®Google Scholar
• Chen C, Liu Y, Chen YZ, Xu JH. C086, a novel analog of curcumin, induces growth inhibition and down-regulation of NFκB in colon cancer cells and xenograft tumors. Cancer Biol Ther. 2011;12(9):797–807. doi:10.4161/cbt.12.9.1767121900746
   PubMed Web of Science ®Google Scholar
• Huang W, Ye M, Zhang LR, et al. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation. Mol Cancer. 2014;13(1):150. doi:10.1186/1476-4598-13-15024927996
   PubMedGoogle Scholar
• Wu LX, Yu J, Chen RJ, et al. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells. Clin Cancer Res. 2015;21(4):833–843. doi:10.1158/1078-0432.CCR-13-331725501124
   PubMed Web of Science ®Google Scholar
• Huang W, Wu QD, Zhang M, et al. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib. Cancer Lett. 2015;356(2):862–871. doi:10.1016/j.canlet.2014.10.04025449780
   PubMed Web of Science ®Google Scholar
• Gao PZ, Wu H, Guo J, Xu YM. Study on the interaction between breviscapinum and bovine serum albumin by fluorescence spectrometry. Chin JMAP. 2012;29(2):106–109. doi:10.13748/j.cnki.issn1007-7693.2012.02.025
   Google Scholar
• Meng A, Wang Y, Brown SA, Van Zant G, Zhou DH. Ionizing radiation and busulfan inhibit murine bone marrow cell hematopoietic function via apoptosis-dependent and -independent mechanisms. Exp Hematol. 2003;31(12):1348–1356. doi:10.1016/j.exphem14662344
   PubMed Web of Science ®Google Scholar
• Chen JJ, Guo QJ, He XM, Yang SX, Chen C, Zhang LR. Study on a screening model for inhibitor of Hsp90 ATPase activity. J Xiamen Univ. 2010;49(5):711–716.
   Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446. doi:10.1158/0008-5472.CAN-09-194720068163
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681. doi:10.1124/pr.58.3.1016968952
   PubMed Web of Science ®Google Scholar
• Patel BB, Sengupta R, Qazi S, et al. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer. 2008;122(2):267–273. doi:10.1002/ijc.2309717918158
   PubMed Web of Science ®Google Scholar
• Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in IFN-α-sensitive and IFN-α-resistant human bladder cancer cells. Mol Cancer Ther. 2007;6(3):1022–1030. doi:10.1158/1535-7163.MCT-06-054517363495
   PubMed Web of Science ®Google Scholar
• Sung B, Kunnumakkara AB, Sethi G, et al. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther. 2009;8(4):959–970. doi:10.1158/1535-7163.MCT-08-090519372569
   PubMed Web of Science ®Google Scholar
• Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. 2005;65(14):6401–6408. doi:10.1158/0008-5472.CAN-05-093316024644
   PubMed Web of Science ®Google Scholar
• Shimamura T, Li DN, Ji HB, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008;68(14):5827–5838. doi:10.1158/0008-5472.CAN-07-542818632637
   PubMed Web of Science ®Google Scholar
• Ahsan A, Ramanand SG, Whitehead C, et al. Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia. 2012;14(8):670–677. doi:10.1593/neo.1298622952420
   PubMed Web of Science ®Google Scholar
• Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 1995;36(4):305–315. doi:10.1007/BF006890487628050
   PubMed Web of Science ®Google Scholar